title: Mast cell survival and mediator secretion in response to hypoxia.
abstract: Tissue hypoxia is a consequence of decreased oxygen levels in different inflammatory conditions, many associated with mast cell activation. However, the effect of hypoxia on mast cell functions is not well established. Here, we have investigated the effect of hypoxia per se on human mast cell survival, mediator secretion, and reactivity. Human cord blood derived mast cells were subjected to three different culturing conditions: culture and stimulation in normoxia (21% O(2)); culture and stimulation in hypoxia (1% O(2)); or 24 hour culture in hypoxia followed by stimulation in normoxia. Hypoxia, per se, did not induce mast cell degranulation, but we observed an increased secretion of IL-6, where autocrine produced IL-6 promoted mast cell survival. Hypoxia did not have any effect on A23187 induced degranulation or secretion of cytokines. In contrast, cytokine secretion after LPS or CD30 treatment was attenuated, but not inhibited, in hypoxia compared to normoxia. Our data suggests that mast cell survival, degranulation and cytokine release are sustained under hypoxia. This may be of importance for host defence where mast cells in a hypoxic tissue can react to intruders, but also in chronic inflammations where mast cell reactivity is not inhibited by the inflammatory associated hypoxia.
authors.affiliation: Clinical Immunology and Allergy Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Gulliksson
authors.forename: Ricardo F S
authors.initials: RF
authors.lastname: Carvalho
authors.forename: Erik
authors.initials: E
authors.lastname: Ullerås
authors.forename: Gunnar
authors.initials: G
authors.lastname: Nilsson
mesh_terms: D000001:Calcimycin / Q000494:pharmacology; D015550:Cell Degranulation / Q000187:drug effects; D015687:Cell Hypoxia; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000378:metabolism; D018836:Inflammation Mediators / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D017730:Ki-1 Antigen / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D008407:Mast Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism*
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D018836:Inflammation Mediators; D015850:Interleukin-6; D017730:Ki-1 Antigen; D008070:Lipopolysaccharides; D000001:Calcimycin
references.citation: Allergy. 2006 Dec;61(12):1473-9
references.pmid: 17073880
references.citation: Biochim Biophys Acta. 2007 Sep;1771(9):1156-65
references.pmid: 17662651
references.citation: Annu Rev Immunol. 2005;23:749-86
references.pmid: 15771585
references.citation: BMC Immunol. 2008 Jan 23;9:2
references.pmid: 18215266
references.citation: J Immunol. 2007 Sep 1;179(5):3276-86
references.pmid: 17709544
references.citation: Cancer Cell. 2004 Dec;6(6):597-609
references.pmid: 15607964
references.citation: Br J Haematol. 2001 Sep;114(3):616-23
references.pmid: 11552987
references.citation: Exp Cell Res. 2006 Jan 15;312(2):145-55
references.pmid: 16289155
references.citation: Gen Pharmacol. 1998 Oct;31(4):617-23
references.pmid: 9792226
references.citation: Trends Immunol. 2004 May;25(5):235-41
references.pmid: 15099563
references.citation: Blood. 1995 Nov 15;86(10):3705-14
references.pmid: 7579337
references.citation: APMIS. 2002 May;110(5):355-71
references.pmid: 12076253
references.citation: Trends Immunol. 2007 May;28(5):234-41
references.pmid: 17400512
references.citation: J Immunol. 2008 Aug 1;181(3):1665-72
references.pmid: 18641302
references.citation: J Biol Chem. 2003 Oct 3;278(40):38607-16
references.pmid: 12874281
references.citation: J Immunol. 2005 Nov 15;175(10):6257-63
references.pmid: 16272275
references.citation: Biochem Biophys Res Commun. 2003 Jul 11;306(4):805-11
references.pmid: 12821113
references.citation: Immunology. 2003 Jan;108(1):89-97
references.pmid: 12519307
references.citation: Cardiovasc Res. 1999 Apr;42(1):104-12
references.pmid: 10435001
references.citation: J Appl Physiol (1985). 2003 Jan;94(1):325-34
references.pmid: 12391033
references.citation: J Clin Invest. 2006 Oct;116(10):2748-56
references.pmid: 16964309
references.citation: J Cardiovasc Pharmacol Ther. 2003 Jun;8(2):135-48
references.pmid: 12808487
references.citation: J Immunol. 1996 Jul 1;157(1):343-50
references.pmid: 8683136
references.citation: Clin Exp Allergy. 2004 Nov;34(11):1660-4
references.pmid: 15544587
references.citation: Pharmacol Ther. 2007 Feb;113(2):229-46
references.pmid: 17046066
references.citation: Circ Res. 2006 Sep 29;99(7):675-91
references.pmid: 17008597
references.citation: Clin Exp Immunol. 2007 Apr;148(1):161-7
references.pmid: 17286758
references.citation: J Allergy Clin Immunol. 2006 Jun;117(6):1277-84
references.pmid: 16750987
references.citation: Nat Rev Immunol. 2004 Oct;4(10):787-99
references.pmid: 15459670
references.citation: Arthritis Rheum. 1984 Aug;27(8):841-4
references.pmid: 6466392
references.citation: Br J Surg. 2003 Dec;90(12):1470-8
references.pmid: 14648724
references.citation: J Immunol. 2004 Jan 1;172(1):593-600
references.pmid: 14688371